Antibody to clotting factor could prevent troubling side effects
By Sharon Kingman
Monday, February 10, 2014
LONDON – Treatment with a specific humanized antibody may be able to prevent the formation of blood clots without increasing the risk of bleeding. If the initial promise of the therapy, which has so far been tested only in animals, is fulfilled, the antibody could one day replace heparin as the treatment of choice for prevention of unwanted blood clots. Researchers working in Sweden, Australia and Germany, who developed the antibody, which is called 3F7, now plan to test its use in phase I trials. The team, led by Thomas Renné, who is professor of clinical chemistry at the University Hospital in Hamburg, Germany, and at the Karolinska Institute in Stockholm, reported their findings in a paper in the Feb. 5, 2014, edition of Science Translational Medicine.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.